<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447379</url>
  </required_header>
  <id_info>
    <org_study_id>3-2017-0230</org_study_id>
    <nct_id>NCT03447379</nct_id>
  </id_info>
  <brief_title>Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent</brief_title>
  <official_title>Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;•Prospective, open label, randomized, multicenter study

        -  Patients treated with a new generation of Everolimus-eluting stents (Synergy®). After
           PTCA, patients are randomized to a group of DAPT for one year or a group of P2Y12
           monotherapy after 3 months of DAPT. After 12 months of PTCA, evaluate major
           cardiovascular events and major bleeding events

        -  This study is to confirm after PTCA, DAPT for three months is not considered to be
           inferior to keeping DAPT for a year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular clinical events (MACCE)</measure>
    <time_frame>between 3 and 12 month after the procedure</time_frame>
    <description>cardiovascular-related death, myocardial infarction, stent thrombosis, stroke, or target lesion revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>between 3 and 12 month after the procedure</time_frame>
    <description>The Bleeding Academic Research Consortium (BARC) type 3 or 5</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1452</enrollment>
  <condition>Coronary Artery Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>P2Y12 monotherapy after 3 months of DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual-antiplatelet therapy for a year</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1. P2Y12 inhibitor monotherapy after 3 months of DAPT</intervention_name>
    <description>P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)
DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year</description>
    <arm_group_label>P2Y12 monotherapy after 3 months of DAPT</arm_group_label>
    <arm_group_label>Dual-antiplatelet therapy for a year</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 19+

          2. Patients treated with a new generation of Evelorimus-eluting stents (Synergy®)

          3. Patients who understand the content of the subject description and voluntarily sign
             the subject

        Exclusion Criteria:

          1. Age 86+

          2. Hemodynamically unstable patient

          3. Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus,
             contrast agent

          4. Patients at high risk of bleeding, anemia, thrombocytopenia

          5. Patients requiring oral anticoagulants

          6. Pregnant women or women of childbearing age

          7. Life expectancy is less than one year

          8. Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin,
             napjodone, ritonavir, atazanavir)

          9. Patients with a history of intracranial hemorrhage

         10. Patients with moderate to severe hepatic impairment

         11. Patients underwent coronary intervention with stenting within 1 year

         12. Patients with left-main lesions requiring coronary intervention

         13. Patients with chronic stricture lesions requiring treatment

         14. Patients with in-stent restenosis in a lesion requiring treatment

         15. Patients with bifurcation lesions requiring stenting in lateral branches

         16. Patients with lesions requiring more than 3 stents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bumkee Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bumkee Hong, MD</last_name>
    <phone>82-2-2019-3311</phone>
    <email>bkhong@yuhs.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bumkee Hong</last_name>
    <phone>82-2-2019-3311</phone>
    <email>bkhong@yuhs.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Souel</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BumKee Hong, MD</last_name>
      <phone>82-2-2019-3311</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Bumkee Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

